Alan B. Lancz & Associates’s Gilead Sciences GILD Stock Holding History

Alan B. Lancz & Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Hold	7,990	–	–	0.88%	23
2026 Q1	$1.11M	Sell	7,990 -800	-9%	-$112K	1.08%	21
2025 Q4	$1.08M	Hold	8,790	–	–	0.95%	22
2025 Q3	$976K	Hold	8,790	–	–	0.88%	27
2025 Q2	$975K	Hold	8,790	–	–	0.98%	25
2025 Q1	$985K	Sell	8,790 -500	-5%	-$51.6K	1.05%	22
2024 Q4	$858K	Sell	9,290 -1,800	-16%	-$162K	0.87%	25
2024 Q3	$930K	Buy	11,090 +500	+5%	+$38.2K	0.85%	28
2024 Q2	$727K	Buy	+10,590	New	+$707K	0.72%	32
2023 Q4	$842K	Sell	10,390 -300	-3%	-$23.3K	0.88%	26
2023 Q3	$801K	Sell	10,690 -300	-3%	-$23.1K	0.91%	25
2023 Q2	$847K	Hold	10,990	–	–	0.91%	26
2023 Q1	$912K	Hold	10,990	–	–	0.95%	22
2022 Q4	$948K	Hold	10,990	–	–	0.96%	24
2022 Q3	$678K	Hold	10,990	–	–	0.8%	31
2022 Q2	$657K	Sell	10,990 -100	-0.9%	-$6.19K	0.65%	35
2022 Q1	$659K	Hold	11,090	–	–	0.58%	43
2021 Q4	$805K	Buy	+11,090	New	+$764K	0.7%	34

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Alan B. Lancz & Associates's GILD Position: Q2 2026 in Review

Alan B. Lancz & Associates held its Gilead Sciences (GILD) position steady in Q2 2026 at 7,990 shares worth $1.01M. The position accounts for 0.88% of the portfolio, ranked #23.

Alan B. Lancz & Associates first reported a position in GILD in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.11M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Alan B. Lancz & Associates held 7,990 shares of Gilead Sciences worth $1.01M as of Q2 2026.
Alan B. Lancz & Associates left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up 0.88% of Alan B. Lancz & Associates's portfolio in Q2 2026, its #23 holding.
Alan B. Lancz & Associates first reported a position in Gilead Sciences in Q4 2021 and has held it in 18 quarters since.
Alan B. Lancz & Associates's Gilead Sciences position peaked at $1.11M in Q1 2026.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Alan B. Lancz & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.